Contineum Therapeutics, Inc.
CTNMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in. The $504.3M market capitalization puts CTNM squarely in small-cap range for its industry. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Market Cap
$504.3M
Beta
0.89
P/E (TTM)
—
P/E (Fwd)
-7.44
EPS (TTM)
$-1.94
EPS (Fwd)
$-1.81
ROE
-26.9%
ROA
-18.2%
Cash
$246.3M
Total Debt
$7.0M
Free CF
-$39.0M
52W Change
204.5%
Annual Financials
Cash vs Debt
With $246.3M in cash and $7.0M in debt, CTNM maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$39.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -26.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, CTNM has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CTNM.